SCHEMBL5233261

SCHEMBL5233261

CCCCc1cccnc1C#N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.48
ALDH1A1 P00352 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
HPGD P15428 3/20 0.46
NPC1 O15118 1/20 0.46
CASP3 P42574 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
MAPK1 P28482 1/20 0.40
ELANE P08246 1/20 0.37
MPO P05164 1/20 0.37
PLCG1 P19174 1/20 0.37
HSD11B1 P28845 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27764936 0.95 CYP11B1 (0.47) CYP11B1ALDH1A1L3MBTL1HPGDNPC1
SCHEMBL9440243 0.93 CYP11B1 (0.46) CYP11B1ALDH1A1L3MBTL1HPGDNPC1
SCHEMBL29907810 0.93 CYP11B1 (0.46) CYP11B1ALDH1A1L3MBTL1HPGDNPC1
SCHEMBL10982801 0.93 CYP11B1 (0.46) CYP11B1ALDH1A1L3MBTL1HPGDNPC1
SCHEMBL10986240 0.87 BID (0.43) CYP11B1ALDH1A1L3MBTL1HPGDNPC1
SCHEMBL10982482 0.85 F7 (0.45) KDM4E
SCHEMBL6510973 0.83 CYP3A4 (0.40) ALDH1A1L3MBTL1HPGDNPC1CASP3
SCHEMBL10982811 0.82 FAAH (0.45) CYP11B1KDM4E
SCHEMBL10988111 0.82 FAAH (0.45) CYP11B1KDM4E
SCHEMBL6109965 0.82 CYP11B1 (0.53) CYP11B1ALDH1A1HPGDELANEMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3203840-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2017-08-16 EP disclosed
WO-2016057572-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MILLER MARK THOMAS (US) 2016-04-14 WO disclosed
CN-1871215-B Cyclic derivatives as modulators of chemokine receptor activity BRISTOL MYERS SQUIBB CO 2011-06-08 CN disclosed
CN-101568532-A Cyclic derivatives as modulators of chemokine receptor activity BRISTOL MYERS SQUIBB CO (US) 2009-10-28 CN disclosed
CN-101351455-A Macrocyclic compounds useful as BACE inhibitors NOVARTIS AG (CH) 2009-01-21 CN disclosed
EP-1656138-A4 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-04-18 EP disclosed
CN-1871215-A Cyclic derivatives as modulators of chemokine receptor activity BRISTOL MYERS SQUIBB CO (US) 2006-11-29 CN disclosed
EP-1656345-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
EP-1656138-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-05-17 EP disclosed
WO-2005020899-A2 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed
WO-2005021500-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-10 WO disclosed